Working… Menu

Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02796105
Recruitment Status : Completed
First Posted : June 10, 2016
Last Update Posted : September 13, 2017
Information provided by (Responsible Party):
Fundació Privada Eugin

Brief Summary:
Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors

Condition or disease Intervention/treatment Phase
Infertility Drug: Progevera Drug: Orgalutran Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 232 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Evaluation of Efficacy and Safety of Medroxiprogesterone Acetate (Progevera 10 mg®) Versus GnRh Antagonist (Orgalutran®) in Ovarian Stimulation Cycles of Oocyte Donors
Actual Study Start Date : June 2016
Actual Primary Completion Date : July 2017
Actual Study Completion Date : July 10, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Progevera
Progevera 10 mg
Drug: Progevera
Active Comparator: Orgalutran
Orgalutran 0.25 mg
Drug: Orgalutran

Primary Outcome Measures :
  1. donor ovarian response [ Time Frame: 1 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Oocyte donors included in the oocyte donation program of Clinica EUGIN.
  • 1st oocyte donation cycle at Clínica EUGIN.

Exclusion Criteria:

  • Polycistic Ovarian syndrome (PCOs).
  • Estradiol levels on day 2 of menstrual cycle >70 pg/ml.
  • Hormone treatments up to 3 months before the oocyte donation cycle.
  • Medical contraindication to the treatments used in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02796105

Layout table for location information
Clinica Eugin
Barcelona, Spain
Sponsors and Collaborators
Fundació Privada Eugin
Layout table for investigator information
Principal Investigator: Rebeca Begueria, Dr Clinica Eugin
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Fundació Privada Eugin Identifier: NCT02796105    
Other Study ID Numbers: BRAKE
First Posted: June 10, 2016    Key Record Dates
Last Update Posted: September 13, 2017
Last Verified: September 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs